Bozić Marija, Hentova-Senćić Paraskeva, Kontić Djordje, Marković Vujica, Marjanović Ivan
Srp Arh Celok Lek. 2011 Jan-Feb;139(1-2):12-7. doi: 10.2298/sarh1102012b.
INTRODUCTION: Argon laser trabeculoplasty (ALT) is an intraocular pressure lowering method that is overall safe and powerful, but often complicated by transient postoperative intraocular pressure rises. In prevention of this complication, we frequently use two potent alpha-adrenergic agonists--brimonidine and apraclonidine. OBJECTIVE: The aim of this study was to compare brimonidine 0.2% and apraclonidine 0.5% efficacy and safety in prevention of intraocular pressure elevation after ALT. METHODS: This was a prospective, randomized, double-masked and comparative study. This study included 27 POAG patients, 15 received 0.2% brimonidine, and 12 received 0.5% apraclonidine before laser surgery (22 eyes in both groups). Intraocular pressure readings were taken 1, 2, 3, 24 hours and 7 days after ALT. Student's t-test was used to analyse data between two groups, and chi2 test to compare data within groups. Value p less than 0.05 was considered statistically significant. RESULTS: We found statistically significantly lower IOP in eyes that received 0.2% brimonidine at readings taken 1 hour after ALT (p = 0.001). There were no statistically significant differences in other IOP readings between two groups. CONCLUSION: A single preoperative drop of brimonidine 0.2% had similar efficacy and safety as apraclonidine 0.5% in preventing transient IOP elevations after ALT.
引言:氩激光小梁成形术(ALT)是一种降低眼压的方法,总体上安全有效,但术后常伴有短暂的眼压升高。为预防这种并发症,我们经常使用两种强效α-肾上腺素能激动剂——溴莫尼定和阿可乐定。 目的:本研究旨在比较0.2%溴莫尼定和0.5%阿可乐定在预防ALT术后眼压升高方面的疗效和安全性。 方法:这是一项前瞻性、随机、双盲对照研究。本研究纳入27例原发性开角型青光眼(POAG)患者,15例在激光手术前使用0.2%溴莫尼定,12例使用0.5%阿可乐定(两组均为22只眼)。在ALT术后1、2、3、24小时及7天测量眼压。采用Student's t检验分析两组间数据,采用卡方检验比较组内数据。p值小于0.05被认为具有统计学意义。 结果:我们发现,在ALT术后1小时测量时,使用0.2%溴莫尼定的眼内眼压在统计学上显著降低(p = 0.001)。两组间其他眼压测量值无统计学显著差异。 结论:术前单次滴注0.2%溴莫尼定在预防ALT术后短暂眼压升高方面与0.5%阿可乐定具有相似的疗效和安全性。
Cochrane Database Syst Rev. 2017-2-23
Korean J Ophthalmol. 1999-12
Cochrane Database Syst Rev. 2022-8-9
Cochrane Database Syst Rev. 2017-2-23